Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17875634 | 0.83 | TSHR (0.40) | TSHRALDH1A1LMNAMAPK1HTT | |
| SCHEMBL24485545 | 0.83 | TSHR (0.44) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL25784322 | 0.81 | TSHR (0.43) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL23412244 | 0.80 | TSHR (0.62) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL13872039 | 0.80 | TSHR (0.44) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL17875653 | 0.80 | TSHR (0.39) | TSHRALDH1A1CYP3A4MAPK1TP53 | |
| SCHEMBL25784890 | 0.79 | TSHR (0.38) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL25993798 | 0.78 | TSHR (0.44) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL26078407 | 0.77 | TSHR (0.45) | TSHRALDH1A1CYP3A4LMNAHPGD | |
| SCHEMBL17875632 | 0.76 | TSHR (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604918-B2 | Carboxylic acid ester/carbamate compound with polymerizable functional group and fluorine atom group, and manufacturing method therefor | UNIMATEC CO., LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160185714-A1 | CARBOXYLIC ACID ESTER/CARBAMATE COMPOUND WITH POLYMERIZABLE FUNCTIONAL GROUP AND FLUORINE ATOM GROUP, AND MANUFACTURING METHOD THEREFOR | UNIMATEC CO., LTD. (JP) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185714-A1 | CARBOXYLIC ACID ESTER/CARBAMATE COMPOUND WITH POLYMERIZABLE FUNCTIONAL GROUP AND FLUORINE ATOM GROUP, AND MANUFACTURING METHOD THEREFOR | FFAR2, DECR2, FFAR1 | TSHR 2203/4885ALDH1A1 557/4885CYP3A4 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.